240 related articles for article (PubMed ID: 37913816)
1. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
[TBL] [Abstract][Full Text] [Related]
3. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
[TBL] [Abstract][Full Text] [Related]
4. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
7. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
8. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
10. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
13. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
[TBL] [Abstract][Full Text] [Related]
17. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
18. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
19. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
20. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
Loza A; Farias R; Gavin N; Wagner R; Hammer E; Shields A
Obstet Gynecol; 2022 Sep; 140(3):447-449. PubMed ID: 36356238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
